437 related articles for article (PubMed ID: 26252323)
21. Correlation Between Uptake of
Li Q; Ma J; Li H; Xu W; Cao Z; Liu S; Chen L; Gao S; Yan T; Li D; Wang X; Yue Y; Zhao Z; Wang X; Yang H; Zhao H; Yu Y; Zhang Y; Fan F; Wang Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033819849067. PubMed ID: 31092140
[TBL] [Abstract][Full Text] [Related]
22. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
[TBL] [Abstract][Full Text] [Related]
23. The value of FDG PET/CT in the initial staging and bone marrow involvement of patients with multiple myeloma.
Sager S; Ergül N; Ciftci H; Cetin G; Güner SI; Cermik TF
Skeletal Radiol; 2011 Jul; 40(7):843-7. PubMed ID: 21229354
[TBL] [Abstract][Full Text] [Related]
24. Whole-body (18)F-FDG PET identifies high-risk myeloma.
Durie BG; Waxman AD; D'Agnolo A; Williams CM
J Nucl Med; 2002 Nov; 43(11):1457-63. PubMed ID: 12411548
[TBL] [Abstract][Full Text] [Related]
25. Comparison of Whole-Body DWI and
Chen J; Li C; Tian Y; Xiao Q; Deng M; Hu H; Wen B; He Y
AJR Am J Roentgenol; 2019 Sep; 213(3):514-523. PubMed ID: 31166755
[No Abstract] [Full Text] [Related]
26. 18F-FDG and 18F-NaF PET/CT Findings of a Multiple Myeloma Patient With Thyroid Cartilage Involvement.
Oral A; Yazici B; Ömür Ö; Comert M; Saydam G
Clin Nucl Med; 2015 Nov; 40(11):873-6. PubMed ID: 26204214
[TBL] [Abstract][Full Text] [Related]
27. 11C-choline vs. 18F-FDG PET/CT in assessing bone involvement in patients with multiple myeloma.
Nanni C; Zamagni E; Cavo M; Rubello D; Tacchetti P; Pettinato C; Farsad M; Castellucci P; Ambrosini V; Montini GC; Al-Nahhas A; Franchi R; Fanti S
World J Surg Oncol; 2007 Jun; 5():68. PubMed ID: 17584499
[TBL] [Abstract][Full Text] [Related]
28. Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma.
Okasaki M; Kubota K; Minamimoto R; Miyata Y; Morooka M; Ito K; Ishiwata K; Toyohara J; Inoue T; Hirai R; Hagiwara S; Miwa A
Ann Nucl Med; 2015 Apr; 29(3):224-32. PubMed ID: 25421383
[TBL] [Abstract][Full Text] [Related]
29. F-18 FDG PET/CT staging of multiple myeloma with diffuse osseous and extramedullary lesions.
Wiesenthal AA; Nguyen BD
Clin Nucl Med; 2007 Oct; 32(10):797-801. PubMed ID: 17885362
[TBL] [Abstract][Full Text] [Related]
30. [18F-fluorodesoxyglucose positron emission tomography/computed tomography in extramedullary multiple myeloma].
Lissarrague E; Fregeiro MS; Binstok Y; Barla C; Cavani M; Frachia F; Ranero S; Servente L; Riva E
Rev Med Chil; 2022 Feb; 150(2):199-205. PubMed ID: 36156646
[TBL] [Abstract][Full Text] [Related]
31. Positive correlation between baseline PET or PET/CT findings and clinical parameters in multiple myeloma patients.
Park S; Lee SJ; Chang WJ; Maeng CH; Hong JY; Choi MK; Kim YS; Jung CW; Jang JH; Kim SJ; Kim WS; Choi JY; Kim K
Acta Haematol; 2014; 131(4):193-9. PubMed ID: 24296366
[TBL] [Abstract][Full Text] [Related]
32. 18F-FDG PET/CT in myeloma with presumed solitary plasmocytoma of bone.
Nanni C; Rubello D; Zamagni E; Castellucci P; Ambrosini V; Montini G; Cavo M; Lodi F; Pettinato C; Grassetto G; Franchi R; Gross MD; Fanti S
In Vivo; 2008; 22(4):513-7. PubMed ID: 18712181
[TBL] [Abstract][Full Text] [Related]
33. [The value of fluorodeoxyglucose positron emission tomography in multiple myeloma].
Adam Z; Bolcák K; Stanícek J; Pour L; Hájek R; Krejcí M; Prásek J; Neubauer J; Mareschova Y; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):207-14. PubMed ID: 16722151
[TBL] [Abstract][Full Text] [Related]
34. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging.
Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME
Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400
[TBL] [Abstract][Full Text] [Related]
35. The role of positron emission tomography with 18F-fluorodeoxyglucose integrated with computed tomography in the evaluation of patients with multiple myeloma undergoing allogeneic stem cell transplantation.
Patriarca F; Carobolante F; Zamagni E; Montefusco V; Bruno B; Englaro E; Nanni C; Geatti O; Isola M; Sperotto A; Buttignol S; Stocchi R; Corradini P; Cavo M; Fanin R
Biol Blood Marrow Transplant; 2015 Jun; 21(6):1068-73. PubMed ID: 25754658
[TBL] [Abstract][Full Text] [Related]
36. Evolution of solitary plasmacytoma of the sternum to multiple myeloma with multifocal extramedullary liver involvement. Contribution of 18F-FDG PET-CT.
Banzo J; Palomera L; Ubieto MA; Bonafonte E; Rambalde EF; Ayala SM
Rev Esp Med Nucl Imagen Mol; 2013; 32(5):328-9. PubMed ID: 23246251
[No Abstract] [Full Text] [Related]
37. Value of 18F-fluorodeoxyglucose uptake in positron emission tomography/computed tomography in predicting survival in multiple myeloma.
Haznedar R; Akı SZ; Akdemir OU; Ozkurt ZN; Ceneli O; Yağcı M; Sucak GT; Unlü M
Eur J Nucl Med Mol Imaging; 2011 Jun; 38(6):1046-53. PubMed ID: 21287167
[TBL] [Abstract][Full Text] [Related]
38. Characterizing and predicting pathologic spine fractures in myeloma patients with FDG PET/CT and MR imaging.
Mulligan M; Chirindel A; Karchevsky M
Cancer Invest; 2011 Jun; 29(5):370-6. PubMed ID: 21599514
[TBL] [Abstract][Full Text] [Related]
39. Application of PET/CT in treatment response evaluation and recurrence prediction in patients with newly-diagnosed multiple myeloma.
Li Y; Liu J; Huang B; Chen M; Diao X; Li J
Oncotarget; 2017 Apr; 8(15):25637-25649. PubMed ID: 27556189
[TBL] [Abstract][Full Text] [Related]
40. Early bone marrow metastasis detection: the additional value of FDG-PET/CT vs. CT imaging.
Evangelista L; Panunzio A; Polverosi R; Ferretti A; Chondrogiannis S; Pomerri F; Rubello D; Muzzio PC
Biomed Pharmacother; 2012 Sep; 66(6):448-53. PubMed ID: 22902054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
